GLP-1s Approved for Weight Loss: Every FDA-Approved Option Explained

GLP-1s Approved for Weight Loss: Every FDA-Approved Option Explained

By Dr. Onikepe Adegbola, MD PhD

The question I hear most often from patients considering weight loss medication is simple: "What's actually approved?" It's a good question, because the range of GLP-1 receptor agonists has expanded rapidly since 2021, and the difference between FDA-approved for weight loss, FDA-approved for diabetes (and used off-label for weight), and not-yet-approved is a distinction that matters — for safety, for insurance, and for expectations.

Here's every GLP-1 and GLP-1-related medication currently approved by the FDA for chronic weight management, along with the ones you'll hear about that aren't there yet.

Currently FDA-Approved GLP-1s for Weight Loss

1. Wegovy (Semaglutide 2.4 mg) — Approved June 2021

Wegovy was the medication that launched the modern obesity pharmacotherapy era. It's a once-weekly subcutaneous injection of semaglutide, the same active molecule in Ozempic but at a higher dose (2.4 mg vs. 0.5–2.0 mg for diabetes).

Key trial data (STEP 1):

• Average weight loss: 14.9% of body weight at 68 weeks
• About one-third of participants lost 20% or more
• Approval criteria: BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity

Wegovy also holds an FDA indication for cardiovascular risk reduction based on the SELECT trial, which showed a 20% reduction in major cardiovascular events. This makes it the first obesity medication with proven heart benefits.

2. Zepbound (Tirzepatide) — Approved November 2023

Zepbound brought a new mechanism: dual GLP-1 and GIP receptor agonism. This dual action appears to enhance both appetite suppression and metabolic improvement beyond what GLP-1 agonism alone achieves.

Key trial data (SURMOUNT-1):

• Average weight loss: 15% (5 mg), 19.5% (10 mg), 20.9% (15 mg) at 72 weeks
• Over half of participants on the highest dose lost 20% or more body weight
• Same approval criteria as Wegovy: BMI ≥ 30, or ≥ 27 with comorbidity

Zepbound is currently the most effective FDA-approved weight loss medication, producing results that approach surgical outcomes.

3. Saxenda (Liraglutide 3.0 mg) — Approved December 2014

Saxenda was the first GLP-1 approved for weight loss, and it represented a significant advance at the time. It's a once-daily injection of liraglutide — the same molecule as Victoza (used for diabetes) but at a higher dose.

Key trial data (SCALE):

• Average weight loss: 5.4% of body weight (8% in the treatment-compliant analysis) at 56 weeks
• About one-third of participants lost 5% or more
• Also approved for adolescents aged 12+ with obesity

Saxenda's efficacy is modest compared to Wegovy and Zepbound. In practice, most prescribers have moved to weekly injectables unless daily dosing is specifically preferred or the patient has insurance coverage only for Saxenda.

GLP-1 Medications Approved for Diabetes (Used Off-Label for Weight Loss)

Ozempic (Semaglutide 0.5–2.0 mg)

Ozempic is the most commonly prescribed semaglutide product, but its FDA approval is for type 2 diabetes, not weight management. It uses the same molecule as Wegovy at lower doses. Many clinicians prescribe it off-label for weight loss when Wegovy isn't available or isn't covered by insurance.

Off-label prescribing is legal and common in medicine. However, it means your insurance may not cover the medication for a weight-loss indication, and the maximum Ozempic dose (2.0 mg) is below the weight-loss-optimized Wegovy dose (2.4 mg).

Mounjaro (Tirzepatide)

Mounjaro is tirzepatide's diabetes brand name, approved for type 2 diabetes in May 2022. It uses the exact same molecule and doses as Zepbound. Like Ozempic/Wegovy, the distinction is the indication — and therefore insurance coverage.

Other GLP-1 Diabetes Medications

Several other GLP-1 receptor agonists are approved for diabetes but rarely used for weight management:

• Trulicity (dulaglutide): Once-weekly. Modest weight loss (~3–5%).
• Byetta/Bydureon (exenatide): The original GLP-1. Less effective for weight loss than newer options.
• Rybelsus (oral semaglutide): An oral form of semaglutide for diabetes. Lower bioavailability means less weight loss than injectable forms, though an oral weight-loss version is in development.

What's Coming: Next-Generation GLP-1s for Weight Loss

The pipeline is active. Several medications in late-stage trials may surpass current options:

Oral Semaglutide (Higher Dose for Obesity)

Novo Nordisk is developing a high-dose oral semaglutide (up to 50 mg daily) specifically for weight loss. Early trial data (OASIS-1) showed about 15% body weight loss at 68 weeks — close to injectable Wegovy, but in a pill. If approved, this could dramatically expand access by removing the injection barrier.

Retatrutide (Triple Agonist)

Eli Lilly's retatrutide targets three receptors: GLP-1, GIP, and glucagon. Phase 2 data showed up to 24% body weight loss at 48 weeks, and the Phase 3 program is underway. If the Phase 3 results hold, retatrutide would be the most effective obesity medication ever tested.

Survodutide (Dual GLP-1/Glucagon Agonist)

Boehringer Ingelheim's survodutide adds glucagon receptor agonism to GLP-1. Phase 2 data showed 14–19% weight loss at 46 weeks. It may also have particular benefits for liver fat reduction (MASLD/MASH).

CagriSema (Semaglutide + Cagrilintide)

Novo Nordisk's combination of semaglutide with an amylin analog. Phase 2 data suggested about 17% weight loss, and Phase 3 trials are ongoing.

Choosing the Right GLP-1 for Weight Loss

With multiple GLP-1s approved for weight loss, how do you choose? In my practice, I consider:

• Efficacy goals: If maximum weight loss is the priority, Zepbound (tirzepatide) currently has the strongest data.
• Cardiovascular risk: Wegovy has the SELECT trial cardiovascular data. Zepbound's cardiovascular outcomes trial is ongoing.
• Insurance coverage: This often drives the decision more than efficacy data. Coverage varies dramatically between plans.
• Side effect tolerance: Patients who couldn't tolerate semaglutide sometimes do better on tirzepatide, and vice versa.
• Administration preference: All current approved options are injectable. Oral options may change the calculus when available.

Regardless of which GLP-1 medication you're on, protecting your lean muscle mass during weight loss is critical. I recommend adequate protein intake — at least 1.0 g per kg of body weight daily — paired with resistance training. For patients who struggle to meet protein goals on suppressed appetite, the GLP-1 Muscle Defense Protocol provides a structured approach to preserving muscle during GLP-1-mediated weight loss.

What to Consider Before Starting a GLP-1 for Weight Loss

Regardless of which specific GLP-1 medication you and your doctor choose, a few considerations apply across the board:

These Are Long-Term Medications

The STEP 1 extension study showed that patients who stopped semaglutide regained approximately two-thirds of the weight they'd lost over the following year. Current evidence suggests GLP-1 medications work best as ongoing therapy, not short-term interventions. Before starting, have a realistic conversation with your prescriber about the long-term plan.

Nutrition Quality Matters Alongside Medication

GLP-1 medications reduce appetite, which reduces caloric intake. But reduced intake without attention to nutrition quality creates problems: muscle loss, vitamin deficiencies, fatigue, and hair thinning. Every patient I put on a GLP-1 gets a conversation about protein targets (minimum 60–80 grams daily) and micronutrient adequacy.

Insurance and Cost Are Real Barriers

Even FDA-approved weight loss medications face inconsistent insurance coverage. Prior authorization is almost universal, step therapy requirements are common, and many patients face out-of-pocket costs of $500–$1,400/month without coverage. This is a systemic problem, not a personal one.

The Non-GLP-1 Context: Other Approved Weight Loss Medications

GLP-1s aren't the only FDA-approved weight loss medications. For completeness:

• Contrave (naltrexone/bupropion): Oral. Average weight loss ~5%. Works on reward pathways.
• Qsymia (phentermine/topiramate): Oral. Average weight loss ~10%. Has more restrictions due to topiramate's teratogenicity.
• Orlistat (Xenical/Alli): Oral. Average weight loss ~3%. Blocks fat absorption. Significant GI side effects.

None of these approach the efficacy of modern GLP-1 medications, which is why the field has shifted so dramatically toward GLP-1-based therapy.

Frequently Asked Questions

Which GLP-1 is most effective for weight loss?

As of current data, tirzepatide (Zepbound/Mounjaro) produces the highest average weight loss among approved GLP-1s — approximately 20.9% at the 15 mg dose over 72 weeks. Semaglutide (Wegovy) produces approximately 14.9% at its maximum dose. Head-to-head trials between the two are not yet complete.

Is Ozempic approved for weight loss?

No. Ozempic is approved for type 2 diabetes only. Wegovy is the semaglutide product approved for weight loss. They contain the same molecule but at different doses and with different FDA indications. Ozempic is commonly prescribed off-label for weight management.

Can I get GLP-1 weight loss medication without diabetes?

Yes. Wegovy and Zepbound are approved for weight management regardless of diabetes status. You need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease, etc.).

Are GLP-1 medications safe long-term?

The longest available data for current GLP-1 weight loss medications extends to about 2–4 years. No unexpected long-term safety signals have emerged. Liraglutide (Saxenda) has been available since 2014, providing the longest track record. However, as with all medications, ongoing surveillance continues.

Will insurance cover GLP-1 medications for weight loss?

Coverage varies enormously between insurance plans. Many commercial plans now cover Wegovy or Zepbound, though often with prior authorization and step therapy requirements. Medicare currently does not cover medications prescribed solely for weight loss, though legislation to change this is under consideration.